Ezogabine: A Novel Antiepileptic for Adjunctive Treatment of Partial-Onset Seizures

被引:22
|
作者
Amabile, Celene M. [1 ]
Vasudevan, Arvind [2 ]
机构
[1] Wingate Univ, Wingate, NC USA
[2] Carolinas Med Ctr NE, Concord, NC USA
来源
PHARMACOTHERAPY | 2013年 / 33卷 / 02期
关键词
antiepileptic; partial seizures; ezogabine; retigabine; Potiga; DOSE-RANGING TRIAL; RETIGABINE;
D O I
10.1002/phar.1185
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Epilepsy is defined as a tendency toward recurrent seizures unprovoked by any systemic or acute neurologic insults. It is a disruption of the electrical conductivity or activity in the brain, resulting in a seizure. In the United States, approximately 120 of every 100,000 people seek medical attention due to new seizure activity. Ezogabine, known as retigabine in Europe, is an ethyl N-(2-amino-4-[{fluorophenyl}methlamino]phenylcarbamate). The drug has been approved by the United States Food and Drug Administration (FDA) and European Medicines Agency for adjunctive treatment of partial-onset seizures in adults. Ezogabine exerts its therapeutic effect by enhancing transmembrane potassium channels (KCNQ ion channels), which is a novel mechanism in comparison with other antiepileptics. There are no specific documented contraindications to ezogabine. Warnings target patients that have benign prostatic hyperplasia or are receiving concomitant anticholinergic drugs due to a risk of urinary retention (2%). The FDA has required that ezogabine be part of a risk evaluation and mitigation strategy program in order to inform health care professionals of the risk of urinary retention. Prescribers should inform patients that ezogabine can cause urinary retention, including urinary hesitation, and instruct them to seek immediate medical attention if these symptoms occur. A medication guide has been developed for distribution to patients.
引用
收藏
页码:187 / 194
页数:8
相关论文
共 50 条
  • [21] Efficacy of antiepileptic drugs in the adjunctive treatment of refractory partial-onset seizures: Meta-analysis of pivotal trials
    Slater, Jeremy
    Chung, Steve
    Huynh, Lynn
    Duh, Mei Sheng
    Gorin, Brian
    McMicken, Carolyn
    Ziemann, Adam
    Isojarvi, Jouko
    EPILEPSY RESEARCH, 2018, 143 : 120 - 129
  • [22] Efficacy of Adjunctive Ezogabine (Retigabine) 600-1200mg/Day by Concomitant Antiepileptic Drug in Adults with Drug-Resistant Partial-Onset Seizures
    Leroy, Robert F.
    Porter, Roger J.
    Shaikh, Soraya
    DeRossett, Sarah E.
    Hall, Susan T.
    NEUROLOGY, 2011, 76 (09) : A289 - A289
  • [23] Lacosamide: Efficacy and safety as oral adjunctive treatment for partial-onset seizures
    Chung, Steve
    Sperling, Michael
    Biton, Victor
    Krauss, Gregory
    Beaman, Margaret
    Hebert, David
    NEUROLOGY, 2008, 70 (11) : A74 - A75
  • [24] Lacosamide: Efficacy and safety as oral adjunctive treatment for partial-onset seizures
    Chung, Steve S.
    Sperling, M.
    Biton, V.
    Krauss, G.
    Beaman, M.
    Hebert, D.
    EPILEPSIA, 2007, 48 : 321 - 321
  • [25] Topiramate as adjunctive therapy in children with partial-onset seizures
    Elterman, R
    Glauser, TA
    Ritter, FJ
    Reife, R
    Wu, SC
    ANNALS OF NEUROLOGY, 1997, 42 (03) : P12 - P12
  • [26] THE ROLE OF LACOSAMIDE AS ADJUNCTIVE THERAPY FOR PARTIAL-ONSET SEIZURES
    Bek, S.
    Koc, G.
    Genc, G.
    Gokcil, Z.
    EPILEPSIA, 2015, 56 : 207 - 207
  • [27] PerampanelAs Adjunctive Therapy in Patients with Partial-Onset Seizures
    Greg L. Plosker
    CNS Drugs, 2012, 26 : 1085 - 1096
  • [28] Perampanel As Adjunctive Therapy in Patients with Partial-Onset Seizures
    Plosker, Greg L.
    CNS DRUGS, 2012, 26 (12) : 1085 - 1096
  • [29] Efficacy and tolerability of brivaracetam as adjunctive treatment for adults with refractory partial-onset seizures
    French, J.
    von Rosenstiel, P.
    EPILEPSIA, 2007, 48 : 78 - 78
  • [30] Long-term adjunctive lacosamide treatment in patients with partial-onset seizures
    Rosenow, F.
    Kelemen, A.
    Ben-Menachem, E.
    McShea, C.
    Isojarvi, J.
    Doty, P.
    ACTA NEUROLOGICA SCANDINAVICA, 2016, 133 (02): : 136 - 144